메뉴 건너뛰기




Volumn 18, Issue 1, 2015, Pages 108-110

Subclinical inflammation with tocilizumab treatment of rheumatoid arthritis: MRI evaluation for 2 years

Author keywords

[No Author keywords available]

Indexed keywords

TOCILIZUMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

EID: 84925947230     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/1756-185X.12460     Document Type: Letter
Times cited : (2)

References (11)
  • 1
    • 79951555321 scopus 로고    scopus 로고
    • Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitors
    • Rendas-Baum R, Wallenstein CV, Koncz T et al. (2011) Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitors. Arthritis Res Ther 13, R25.
    • (2011) Arthritis Res Ther , vol.13 , pp. R25
    • Rendas-Baum, R.1    Wallenstein, C.V.2    Koncz, T.3
  • 2
    • 34447300492 scopus 로고    scopus 로고
    • Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab
    • Nishimoto N, Hashimoto J, Miyasaka N et al. (2007) Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 66, 1162-7.
    • (2007) Ann Rheum Dis , vol.66 , pp. 1162-1167
    • Nishimoto, N.1    Hashimoto, J.2    Miyasaka, N.3
  • 4
    • 79951497910 scopus 로고    scopus 로고
    • Synovitis and osteitis are very frequent in rheumatoid arthritis clinical remission: results from an MRI study of 294 patients in clinical remission or low disease activity state
    • Gandjbakhch F, Conaghan PG, Ejbjerg B et al. (2011) Synovitis and osteitis are very frequent in rheumatoid arthritis clinical remission: results from an MRI study of 294 patients in clinical remission or low disease activity state. J Rheumatol 38, 2039-44.
    • (2011) J Rheumatol , vol.38 , pp. 2039-2044
    • Gandjbakhch, F.1    Conaghan, P.G.2    Ejbjerg, B.3
  • 5
    • 54949135724 scopus 로고    scopus 로고
    • An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis
    • Brown AK, Conaghan PG, Karim Z et al. (2008) An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum 58, 2958-67.
    • (2008) Arthritis Rheum , vol.58 , pp. 2958-2967
    • Brown, A.K.1    Conaghan, P.G.2    Karim, Z.3
  • 6
    • 84855269285 scopus 로고    scopus 로고
    • Power Doppler ultrasound, but not low-field magnetic resonance imaging, predicts relapse and radiographic disease progression in rheumatoid arthritis patients with low levels of disease activity
    • Foltz V, Gandjbakhch F, Etchepare F et al. (2012) Power Doppler ultrasound, but not low-field magnetic resonance imaging, predicts relapse and radiographic disease progression in rheumatoid arthritis patients with low levels of disease activity. Arthritis Rheum 64, 67-76.
    • (2012) Arthritis Rheum , vol.64 , pp. 67-76
    • Foltz, V.1    Gandjbakhch, F.2    Etchepare, F.3
  • 7
    • 84880797201 scopus 로고    scopus 로고
    • Therapeutic efficacy of tocilizumab in patients with rheumatoid arthritis refractory to anti-tumor-necrosis-factor inhibitors: 1 year follow-up with low-field extremity MRI
    • Suzuki T, Horikoshi M, Sugihara M et al. (2013) Therapeutic efficacy of tocilizumab in patients with rheumatoid arthritis refractory to anti-tumor-necrosis-factor inhibitors: 1 year follow-up with low-field extremity MRI. Mod Rheumatol 23, 782-7.
    • (2013) Mod Rheumatol , vol.23 , pp. 782-787
    • Suzuki, T.1    Horikoshi, M.2    Sugihara, M.3
  • 8
    • 78349276169 scopus 로고    scopus 로고
    • New low-field extremity MRI, compacTscan: comparison with whole-body 1.5 T conventional MRI
    • Suzuki T, Ito S, Handa S et al. (2010) New low-field extremity MRI, compacTscan: comparison with whole-body 1.5 T conventional MRI. Mod Rheumatol 20, 331-6.
    • (2010) Mod Rheumatol , vol.20 , pp. 331-336
    • Suzuki, T.1    Ito, S.2    Handa, S.3
  • 9
    • 68549118897 scopus 로고    scopus 로고
    • A new low-field extremity magnetic resonance imaging and proposed compact MRI score: evaluation of anti-tumor necrosis factor biologics on rheumatoid arthritis
    • Suzuki T, Ito S, Handa S et al. (2009) A new low-field extremity magnetic resonance imaging and proposed compact MRI score: evaluation of anti-tumor necrosis factor biologics on rheumatoid arthritis. Mod Rheumatol 19, 358-65.
    • (2009) Mod Rheumatol , vol.19 , pp. 358-365
    • Suzuki, T.1    Ito, S.2    Handa, S.3
  • 10
    • 84893538112 scopus 로고    scopus 로고
    • Determining a magnetic resonance imaging inflammatory activity acceptable state without subsequent radiographic progression in rheumatoid arthritis: results from a followup MRI study of 254 patients in clinical remission or low disease activity
    • Gandjbakhch F, Haavardsholm EA, Conaghan PG et al. (2014) Determining a magnetic resonance imaging inflammatory activity acceptable state without subsequent radiographic progression in rheumatoid arthritis: results from a followup MRI study of 254 patients in clinical remission or low disease activity. J Rheumatol 41, 398-406.
    • (2014) J Rheumatol , vol.41 , pp. 398-406
    • Gandjbakhch, F.1    Haavardsholm, E.A.2    Conaghan, P.G.3
  • 11
    • 84897569032 scopus 로고    scopus 로고
    • Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study
    • Nishimoto N, Amano K, Hirabayashi Y et al. (2014) Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study. Mod Rheumatol 24, 17-25.
    • (2014) Mod Rheumatol , vol.24 , pp. 17-25
    • Nishimoto, N.1    Amano, K.2    Hirabayashi, Y.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.